中国医科大学学报  2025, Vol. 54 Issue (4): 359-363

文章信息

樊维娟, 邓小倩, 郑立春, 欧阳向柳
FAN Weijuan, DENG Xiaoqian, ZHENG Lichun, OUYANG Xiangliu
超声及超声造影在鉴别胰腺神经内分泌瘤与胰腺导管腺癌中的临床价值
Clinical value of ultrasound and contrast enhanced ultrasound in the differential diagnosis of pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma
中国医科大学学报, 2025, 54(4): 359-363
Journal of China Medical University, 2025, 54(4): 359-363

文章历史

收稿日期:2024-06-06
网络出版时间:2025-04-10 11:25:13
超声及超声造影在鉴别胰腺神经内分泌瘤与胰腺导管腺癌中的临床价值
1. 唐山中心医院超声医学科,河北 唐山 063008;
2. 唐山市工人医院超声医学科,河北 唐山 063003;
3. 唐山市工人医院核医学科,河北 唐山 063003
摘要目的 探讨超声及超声造影在胰腺神经内分泌瘤(PNET)与胰腺导管腺癌(PDAC)鉴别诊断中的临床价值。方法 回顾性分析经病理确诊且临床资料、超声及超声造影资料完整的PNET患者74例,并选取74例PDAC患者作为对照组,比较2组患者的临床指标、超声及超声造影表现,2组间计量资料比较采用t检验,计数资料比较采用χ2检验或Fisher’s确切概率法。结果 74例PNET均为单发病灶,胰头18例、胰体26例、胰尾30例,PDAC也均为单发病灶,胰头52例、胰体8例、胰尾14例;在超声表现方面,PNET组病灶低回声、形态规则、边界清晰、胰管扩张或截断,血流信号所占比例分别为86.49%、83.78%、78.38%、18.92%、32.43%,PDAC组分别为94.59%、29.73%、27.03%、75.68%、21.62%,2组在病灶发病部位、形态是否规则、边界是否清晰、胰管是否扩张或截断方面差异有统计学意义(χ2分别为31.862、44.048、39.141、47.815,P均 < 0.05),而在回声及血流信号方面差异无统计学意义(χ2分别为2.840、2.193,P均 > 0.05)。52例PNET行超声造影检查,其中动脉期呈高增强表现38例,呈等增强表现14例,静脉期呈等增强表现40例,呈低增强表现12例;74例PDAC行超声造影检查,其中动脉期呈低增强表现70例、静脉期呈低增强表现72例。2组动脉期、静脉期的超声增强方式比较差异均有统计学意义(χ2分别为56.582和37.852,P均 < 0.05)。结论 PNET的超声及超声造影图像表现具有一定特征性,结合造影增强方式在与PDAC鉴别诊断中有一定临床价值。
关键词胰腺肿瘤    神经内分泌瘤    胰腺导管腺癌    超声    超声造影    
Clinical value of ultrasound and contrast enhanced ultrasound in the differential diagnosis of pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma
1. Department of Ultrasound, Tangshan Central Hospital, Tangshan 063008, China;
2. Department of Ultrasound, Tangshan Gongren Hospital, Tangshan 063003, China;
3. Department of Nuclear Medicine, Tangshan Gongren Hospital, Tangshan 063003, China
Abstract: Objective To investigate the value of ultrasound and contrast enhanced ultrasound (CEUS) in the differential diagnosis of pancreatic neuroendocrine tumor (PNET) and pancreatic ductal adenocarcinoma (PDAC). Methods A retrospective analysis was performed on the clinical data, ultrasound findings, and CEUS findings of 74 patients with PNET and their characteristic manifestations were analyzed and compared with those of 74 patients with PDAC. Data of the two groups were compared using the t-test and χ2 test, or Fisher's exact test. Results There were 18, 26, and 30 patients with PNET lesions and 52, 8, and 14 patients with PDAC located in the head, body, and tail of the pancreas, respectively. The patients with hypoechoic lesions, regular lesion morphology, clear boundaries, pancreatic duct dilatation or cutoff, and blood flow signal accounted for 86.49%, 83.78%, 78.38%, 18.92% and 32.43% in the PNET group, respectively, whereas in the PDAC group, such patients accounted for 94.59%, 29.73%, 27.03%, 75.68% and 21.62%, respectively. There was a significant intergroup differences in lesion location, morphology, boundaries and pancreatic duct dilatation or cutoff (χ2=31.862, χ2=44.048, χ2=39.141, and χ2=47.815, respectively, P < 0.05), with no significant differences in hypoechoic and blood flow signal (χ2=2.840 and χ2=2.193, P > 0.05). Among the 52 patients with PNET, CEUS showed that 38 had hyperenhancement and 14 had iso-enhancement in the arterial phase, whereas 40 had iso-enhancement and 12 had hypoenhancement in the venous phase. CEUS was performed in 74 patients with PDAC; 70 patients showed hypoenhancement in the arterial phase and 72 showed hypoenhancement in the venous phase. There were significant differences in the enhancement pattern in the arterial and venous phases between the two groups (χ2=56.582 and χ2=37.852, P < 0.05). Conclusion Ultrasound and CEUS revealed some characteristics of PNET that can be used for the differential diagnosis of PNET and PDAC, when combined with enhancement pattern.

胰腺神经内分泌瘤(pancreatic neuroendocrine tumor,PNET)发病率低,仅占胰腺肿瘤的1%~2%[1],术前诊断比较困难,根据是否伴有血清相关激素水平增高分为功能性和无功能性,无功能性的神经内分泌瘤缺乏特异性的临床表现,更加容易漏诊和误诊[2]。PNET为惰性肿瘤,进展缓慢,但也存在远处转移的风险。其中以肝脏转移最为常见,其次为脑、骨骼、肺等部位,影响患者的生存期及生活质量[3-4]。PNET与临床中常见的胰腺导管腺癌(pancreatic ductal adenocarcinoma,PDAC)治疗策略及预后均不同,因此,早期发现和诊断PNET并与PDAC准确鉴别在临床上有重要意义。超声检查具有方便、经济、无不良反应等优点;而超声造影可以实时观察病灶强化情况,并可重复操作,对胰腺病变的鉴别诊断具有较高临床价值[5]。本研究回顾性分析了74例无功能性PNET的常规超声及超声造影表现,探讨超声及超声造影在PNET与PDAC鉴别诊断中的临床价值。

1 材料与方法 1.1 一般资料

回顾性分析2020年1月至2023年12月于唐山中心医院和唐山市工人医院就诊的74例PNET患者。其中,男30例,女44例,年龄27~72(52.6±8.3)岁。纳入标准:超声检查前未经治疗的胰腺病变患者,患者均经手术病理或穿刺病理确诊,并具有明确的最终病理结果;术前或穿刺前行常规超声检查,或同期(2周内)行超声造影检查;临床资料完整。选取同期74例经手术或穿刺病理确诊的PDAC患者作为对照组,年龄51~76岁,平均(64.7±10.5)岁,男46例,女28例。本研究经唐山市工人医院伦理委员会审批通过(批号:GRYY-LL-2019-39),患者均签署知情同意书。

1.2 仪器与方法

超声检查采用GE Logiq E9、Philips Iu22超声诊断仪,选择腹部探头,探头频率为1~5 MHz。患者取仰卧位,将探头置于腹部并多切面扫查,重点观察病灶的位置、边界、形态、大小、回声、主胰管有无扩张及血流信号情况。超声造影检查时,造影剂使用Sonovue,用5 mL生理盐水稀释,充分振荡使其溶解,检查时经患者肘正中静脉快速团注(1.5~2 mL),随后用5 mL生理盐水快速冲洗套管针,在注射造影剂的同时开始计时,连续不间断观察病灶的血流灌注情况,存储并记录3 min内病灶的动态增强-消退模式。

1.3 图像分析

由2名具有高级职称的超声医师对常规超声及超声造影图像进行分析,观察病灶的常规彩色多普勒超声表现,超声造影检查主要观察病灶的增强程度与模式,胰腺造影时相分为动脉期(10~30 s)和静脉期(31~120 s),并将病灶与周边正常胰腺组织增强情况进行对比,根据对比情况将病灶的超声造影增强程度分为高增强、等增强和低增强。

1.4 统计学分析

采用SPSS 22.0软件进行统计学分析。其中,符合正态分布的计量资料采用x±s表示,不符合正态分布采用MP25~P75)表示,计数资料采用率(%)表示,2组比较采用t检验或秩和检验、χ2检验或Fisher’s确切概率法,P < 0.05为差异有统计学意义。

2 结果 2.1 2组一般临床资料比较

74例PNET患者均为单发病灶,胰头18例、胰体26例、胰尾30例,病灶最大径2.4~10.9 cm,平均(5.5±2.4)cm。52例通过手术切除取得病理结果,22例通过穿刺活检取得病理结果;病理G1级26例(26/74,35.14%)、G2级34例(34/74,45.95%)、G3级14例(14/74,18.91%)。74例PDAC患者均为单发病灶,胰头52例,胰体8例,胰尾14例,最大径1.7~6.8 cm,平均(4.1±1.9)cm。2组性别、病灶最大径、病灶发生部位比较差异均有统计学意义(P均 < 0.05),见表 1

表 1 2组临床指标与常规超声特征比较 Tab.1 Comprasion of clinical data and ultrasonographic characteristics between the two groups
Item PNET group(n = 74) PDAC group(n = 74) χ2/t P
Sex [n(%)] 6.924 0.009
    Male 30(40.54) 46(62.16)
    Female 44(59.46) 28(37.84)
Maximum diameter(cm) 5.5±2.4 4.1±1.9 2.437 0.026
Lesion location [n(%)] 31.862 < 0.001
    Head of pancreas 18(24.32) 52(70.27)
    Body of pancreas 26(35.14) 8(10.81)
    Tail of pancreas 30(40.54) 14(18.92)
Hypoechoic [n(%)] 2.840 0.092
    Low echo 64(86.49) 70(94.59)
    Cystic-solid mixed echo 10(13.51) 4(5.41)
Boundary [n(%)] 39.141 < 0.001
    Clear 58(78.38) 20(27.03)
    Unclear 16(21.62) 54(72.97)
Morphology [n(%)] 44.048 < 0.001
    Regular 62(83.78) 22(29.73)
    Unregular 12(16.22) 52(70.27)
Pancreatic duct dilatation or cutoff [n(%)] 47.815 < 0.001
    Yes 14(18.92) 56(75.68)
    No 60(81.08) 18(24.32)
Blood flow signal [n(%)] 2.193 0.139
    Abundant 24(32.43) 16(21.62)
    Unabundant 50(67.57) 58(78.38)

2.2 2组常规超声影像表现比较

74例PNET患者中病灶呈低回声64例,形态规则62例,边界清晰58例,无胰管扩张或截断60例,彩色多普勒血流成像(color Doppler flow imaging,CDFI)显示血流信号不丰富50例。而74例PDAC患者中病灶呈低回声70例,形态不规则52例,边界不清晰54例,伴有胰管扩张或截断56例,CDFI显示血流信号不丰富58例。2组在病灶形态是否规整、边界是否清晰、胰管是否扩张或截断方面的差异均有统计学意义(P均 < 0.05),而在病灶回声及病灶内血流信号方面的差异无统计学意义(P均 > 0.05),见表 1

2.3 2组超声造影表现比较

74例PNET患者中,有52例同期进行了超声造影检查。其中,在造影动脉期呈高增强表现38例(38/52,73.08%),呈等增强表现14例(14/52,26.92%),在造影静脉期呈等增强表现40例(40/52,76.92%),呈低增强表现12例(12/52,23.08%),典型病例见图 1。74例PDAC患者均行超声造影检查,在造影动脉期呈低增强表现70例(70/74,94.59%)、呈等增强表现4例(4/74,5.41%),在造影静脉期呈低增强表现72例(72/74,97.30%)、呈等增强表现2例(2/74,2.70%),典型病例见图 2。PNET与PDAC患者造影增强方式比较结果显示,两者超声造影表现在动脉期增强方式和静脉期增强方式的差异均存在统计学意义(χ2分别为56.582和37.852,P均 < 0.001)。

A,hypoechoic mass at the tail of the pancreatic body observed on conventional ultrasound;B,mass showing high enhancement in the arterial phase of contrast-enhanced ultrasound;C,mass showing equal enhancement in the venous phase of contrast-enhanced ultrasound. The white arrows indicate the lesion site. 图 1 53岁PNET男性患者超声造影动脉期及静脉期图像 Fig.1 Contrast-enhanced ultrasound image at the arterial and venous phases of a 53-year-old male patient with PNET

A,hypoechoic nodule at the head of the pancreas on conventional ultrasound;B,nodule showing low enhancement in the arterial phase of contrast-enhanced ultrasound;C,nodule showing low enhancement in the venous phase on contrast-enhanced ultrasound. The white arrows indicate the lesion site. 图 2 65岁PDAC男性患者超声造影动脉期及静脉期图像 Fig.2 Contrast-enhanced ultrasound image at arterial and venous phases of a 65-year-old male patient with PDAC

3 讨论

PNET起源于胰腺肽能神经元的神经内分泌细胞,WHO病理分级依据肿瘤核分裂相分为G1、G2和G3 3级[6-7]。PNET可发生于胰腺的任何部位[8],本研究发现PENT好发于胰体尾部(75.68%,56/74),有别于PDAC(29.73%,22/74)。PNET常规超声多表现为低回声,回声可均匀或不均匀,这主要取决于PNET肿瘤内间质组织与肿瘤细胞的数量和比例。当肿瘤体积较大发生坏死液化时,可表现为囊实混合性回声。本组64例PNET超声显示为低回声,与PDAC低回声比例一致,差异无统计学意义,另外10例为囊实混合回声,肿瘤最大径均 > 7 cm,与文献[9]报道一致。

PNET很少引起胰管扩张,超声检查能较好地显示胰管是否扩张或截断,本组74例仅14例伴主胰管扩张。与PDAC有统计学差异(18.92% vs. 75.68%,P < 0.001),主要是因为PNET不起源于胰腺导管,一般不会阻塞引起远端胰管扩张。PDAC起源于胰腺导管,常常引起胰管的阻塞,从而引起远端胰管的扩张。超声显示PNET肿瘤的边界、形态与其病理分级相关[10],G1级及大部分G2级侵袭性相对较弱,多表现为形态规则,边界清晰;另有少部分G2级及G3级PNET呈明显侵袭性表现,多表现为边界欠清晰,形态欠规则;而PDAC则具有明显的侵袭性,多表现为形态不规则、边界不清晰。本组74例PNET中有62例形态规则,58例病灶边界清晰,与PDAC病灶的形态、边界表现均存在统计学差异(P均 < 0.05),可能与本组病例中G1、G2级病例较多有关。PNET为富血供肿瘤[11],PDAC为乏血供肿瘤,而本组PNET病例中24例表现为血流信号丰富,所占比例与PDAC中比例差异无统计学意义(32.43% vs. 21.62%,P = 0.295),这可能与以下因素有关:(1)本组部分PNET病例病灶为囊实混合,导致血流信号减少;(2)病灶较大时出现囊变坏死导致血流信号不丰富;(3)部分肿瘤位置较深、体积较小血流信号显示不好。

本研究中,52例PNET患者进行了超声造影检查,在动脉期38例(73.08%)呈高增强表现,14例(26.92%)呈等增强表现,在静脉期40例(76.92%)呈等增强表现,12例(23.08%)呈低增强表现,与文献[12]报道一致。PDAC为乏血供肿瘤,不会刺激大量血管增生,并且肿瘤细胞生长迅速,正常的血管系统无法适应,从而导致血液供应不足,在超声造影动脉期及静脉期多表现为低增强。本研究74例PDAC中,70例(94.59%)动脉期呈低增强表现,72例(97.30%)静脉期呈低增强表现,2组增强方式差异有统计学意义,这对于PNET与PDAC的鉴别诊断有一定临床价值,与以往研究[13]结果一致。

综上所述,PNET在超声上多表现为胰腺局部实性病灶,常呈低回声,病灶形态规则、边界清晰,多不伴胰管扩张或截断,超声造影上则多以动脉期高增强、静脉期等增强表现为主,这些特征在与PDAC的鉴别诊断中有一定临床价值。

参考文献
[1]
MOHINDROO C, MCALLISTER F, DE JESUS-ACOSTA A. Genetics of pancreatic neuroendocrine tumors[J]. Hematol Oncol Clin North Am, 2022, 36(5): 1033-1051. DOI:10.1016/j.hoc.2022.07.005
[2]
HOFLAND J, FALCONI M, CHRIST E, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes[J]. J Neuroendocrinol, 2023, 35(8): e13318. DOI:10.1111/jne.13318
[3]
刘荣, 沈晓菲, 刘渠. 胰腺神经内分泌肿瘤肝转移的多元饱和治疗[J]. 中华医学杂志, 2021, 101(32): 2497-2501. DOI:10.3760/cma.j.cn112137-20210128-00267
[4]
SHAH MH, GOLDNER WS, BENSON AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 202, 19(7): 839-868. DOI:10.6004/jnccn.2021.0032
[5]
WANG YJ, LI GH, YAN K, et al. Clinical value of contrast-enhanced ultrasound enhancement patterns for differentiating solid pancreatic lesions[J]. Eur Radiol, 2022, 32(3): 2060-2069. DOI:10.1007/s00330-021-08243-8
[6]
CONSTANTIN AL, CAZACU I, BURTEA DE, et al. Quantitative contrast-enhanced endoscopic ultrasound in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors: can we predict survival using perfusion parameters? A pilot study[J]. Med Ultrason, 2022, 24(4): 393-398. DOI:10.11152/mu-3503
[7]
RINDI G, METE O, UCCELLA S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms[J]. Endocr Pathol, 2022, 33(1): 115-154. DOI:10.1007/s12022-022-09708-2
[8]
YANG DH, WANG DS, QIU YJ, et al. Incidental nonfunctioning pancreatic neuroendocrine tumors: contrast enhanced ultrasound features in diagnosis1[J]. Clin Hemorheol Microcirc, 2022, 80(4): 343-352. DOI:10.3233/CH-211269
[9]
缪飞, 林晓珠. 胰腺神经内分泌肿瘤影像学分级再认识[J]. 中华医学杂志, 2022, 102(14): 988-991. DOI:10.3760/cma.j.cn112137-20220210-00280
[10]
HUANG JZ, CHEN J, XU M, et al. Contrast-enhanced ultrasonography findings correlate with pathologic grades of pancreatic neuroendocrine tumors[J]. Ultrasound Med Biol, 2021, 47(8): 2097-2106. DOI:10.1016/j.ultrasmedbio.2021.02.013
[11]
马娜, 李义兴, 徐一文, 等. 多层螺旋CT与MRI对胰腺神经内分泌肿瘤病理分级和肿瘤血供评估的前瞻性研究[J]. 分子影像学杂志, 2023, 46(1): 129-134. DOI:10.12122/j.issn.1674-4500.2023.01.25
[12]
杨道辉, 韩序, 张琪, 等. 胰腺神经内分泌肿瘤CEUS表现与病理学分级的相关性研究[J]. 肿瘤影像学, 2021, 30(4): 237-244. DOI:10.19732/j.cnki.2096-6210.2021.04.002
[13]
DONG Y, YANG DH, TIAN XF, et al. Pancreatic neuroendocrine tumor: prediction of tumor grades by radiomics models based on ultrasound images[J]. Br J Radiol, 2023, 96(1149): 20220783. DOI:10.1259/bjr.20220783